Serum Creatinine vs. Cystatin C: Key Differences
Cystatin C is a superior marker of kidney function compared to serum creatinine because it is independent of muscle mass, age, sex, and diet, making it more accurate for GFR estimation, particularly when creatinine-based estimates are unreliable. 1, 2
What They Are
Serum Creatinine:
- A waste product from muscle metabolism
- Filtered by the glomerulus but also secreted by renal tubules
- Heavily influenced by non-GFR factors: muscle mass, age, sex, diet (especially protein intake), and certain medications
- Standard initial test for kidney function assessment 3, 2
Cystatin C:
- A low molecular weight protein produced by all nucleated cells at a constant rate
- Freely filtered by the glomerulus, completely reabsorbed and catabolized by tubular cells (does not return to bloodstream)
- Independent of muscle mass, age, sex, and dietary protein intake
- More expensive and less widely available 4
Clinical Accuracy Differences
Cystatin C demonstrates superior performance:
- Meta-analysis shows cystatin C has stronger correlation with measured GFR (r=0.816) compared to creatinine (r=0.742) 5
- Better diagnostic accuracy (90% vs 77% for creatinine) in detecting reduced GFR 6
- More sensitive for detecting early kidney dysfunction, particularly in diabetic patients 6
- Less interassay variability compared to creatinine (which can have up to 25% variability at low concentrations) 4
When to Use Each Marker
Use Creatinine-based eGFR for:
- Initial screening in all patients 3, 2
- Routine monitoring when muscle mass and other confounders are stable
Use Cystatin C (or combined creatinine-cystatin C equations) when creatinine is unreliable: 1, 2
- Body composition extremes: Eating disorders, extreme athletes/bodybuilders, amputations, spinal cord injury with paralysis, class III obesity
- Muscle wasting conditions: Malnutrition, chronic illness, cirrhosis, advanced age, sarcopenia
- Dietary factors: Very low protein diets, vegetarian diets, high protein/creatine supplement use
- Critical illness: Hospitalized patients with rapidly changing kidney function 7, 8
- Drug dosing decisions: Particularly for nephrotoxic drugs where accuracy is critical 4, 9
The Combined Approach: Most Accurate
The 2024 KDIGO guideline recommends using equations combining both creatinine AND cystatin C (eGFRcr-cys) when GFR accuracy affects clinical decisions 1, 2. This combined approach:
- Provides the most accurate GFR estimation
- Reduces bias compared to either marker alone
- Improves risk stratification for mortality and cardiovascular outcomes 10, 11
The eGFR Difference: A Novel Risk Marker
The difference between cystatin C-based eGFR and creatinine-based eGFR (eGFRdiff = eGFRcys - eGFRcr) has emerged as an independent predictor of outcomes:
- Negative difference (cystatin C shows worse function): Associated with higher mortality risk, particularly in cirrhosis and heart failure 12, 13
- Positive difference (creatinine shows worse function): Associated with lower cardiovascular risk 13
- This difference reflects non-GFR factors (frailty, inflammation, muscle mass) that independently predict outcomes 1, 12
Practical Implementation Algorithm
- Start with creatinine-based eGFR for all patients 2
- Add cystatin C measurement if:
- Use combined eGFRcr-cys equation when both markers available 1, 2
- Consider measured GFR (inulin or 51Cr-EDTA clearance) only when even cystatin C-based estimates are unreliable and treatment decisions depend on precise GFR 3, 2
Important Caveats
- Cystatin C can be affected by thyroid dysfunction, high-dose corticosteroids, severe inflammation, and smoking (though less than creatinine) 1, 14
- In postrenal obstruction, the discrepancy between creatinine and cystatin C can predict recovery of renal function after intervention 15
- Cystatin C is not yet universally available in all laboratories, limiting widespread implementation 10, 11